Asper Biotech has updated its Ashkenazi Jewish Diseases Test to include mutations in the BRCA1, BRCA2, and LCA5 genes that are common in the Ashkenazi Jewish population. Asper's test now detects up to 112 variants in 27 genes. The test is run using arrayed primer extension and enables the analysis of the most common mutations associated with severe disorders in the Ashkenazi Jewish population, such as cystic fibrosis, Tay-Sachs disease, maple syrup urine disease, and others.
New Products: Asper Biotech's Ashkenazi Jewish Diseases Test
May 20, 2014